ATN-031 First-in-class Macrophage Activator Targeting CD24-expressing Solid Tumors

Summary and Differentiations

"Don’t Eat Me"

  • Reduced phagocytosis
  • M2-like Tumor Associated Macrophage
  • Immunosuppressive Tumor Microenvironment
  • Less tumor antigen presentation
  • In-activated T and NK cells

"Eat Me"

  • Increased phagocytosis
  • M1-like Tumor Associated Macrophage
  • Pro-inflammatory Tumor Microenvironment
  • Enhanced Tumor Antigen presentation
  • Activated T and NK cells

ATN-031: Advancing Through Phase I "PERFORM" with Key Milestones Ahead

Phase I Open Label, Multi-center Dose-finding Study Initiated in the U.S.*

Phase la: Dose Escalation

Primary objectives:Safety, tolerability. Define MTD and RP2D

Secondary objectives:Evaluate preliminary efficacy and pharmacology

Phase lb: Dose Expansion

RP2D dose evaluation as monotherapy or combo with chemotherapy or immunotherapy

Completed the First Dosing Cohort in the Phase I Dose Escalation of "PERFORM" Trial; Periodic Data Update Through 2024/2025

ADA: anti-drug antibody: MTD = maximally tolerated dose, RP2D = recommended phase 2 dose

CD24 Has Higher Tumor Expression Compared to CD47

Comparison Analysis

  • CD24 showed much higher tumor expression (TCGA) and narrower normal tissue distribution (GTEx), with significantly lower normal heart and CNS expression, compared with CD47
  • Anti-CD24 potentially has a larger therapeutic window compared with anti-CD47

A 20-hour Time-Lapse Imaging of ATN-031-Induced Phagocytosis

  • Phagocytosis occurred within 5 minutes after the addition of ATN-031
  • Leukemia cells were completely digested within 10 hours

+ ATN-031

5 minutes

30 minutes

1 hour

5 hours

10 hours

20 hours

+ lgG-Ctrl

5 minutes

30 minutes

1 hour

5 hours

10 hours

20 hours